Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deuterated etifoxine
- Development stage
- Unknown
- Lead developer
- Gaba Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GRX-917 is a deuterated analog of etifoxine, an anxiolytic drug originally approved in France. It is under development for the treatment of anxiety disorders and mood disorders. The drug acts as a positive allosteric modulator of the GABA-A receptor and as a ligand for the translocator protein (TSPO), which stimulates endogenous neurosteroid synthesis, particularly allopregnanolone. These neurosteroids further potentiate GABA-A receptor activity, contributing to anxiolytic effects. Deuteration improves pharmacokinetic properties such as half-life and dosing frequency compared to non-deuterated etifoxine, potentially enhancing patient compliance. GRX-917 has shown favorable tolerability in phase 1 trials with minimal sedative side effects[1][2][3][5][6].
- Other names
- etifoxine deuterated
02
Targets
GABRR (GABA-A receptor subunit rho)TSPO (Translocator Protein (18 kDa))
Beyond the preview
Go deeper on Deuterated etifoxine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Deuterated etifoxine.